Syner-G BioPharma Purchases Impact Pharmaceutical Services

Syner-G BioPharma Group, a provider of chemistry, manufacturing, and controls (CMC) technical, regulatory, and compliance consulting services for the pharmaceutical and biotechnology sectors, has acquired Impact Pharmaceutical Services. Impact handles the outsourced medical writing, regulatory strategy, and regulatory publishing and submission needs of pharma and biotech companies, from the pre-investigational new drug application (pre-IND) through post-marketing of drugs and biologics.

Both parties, the release says, have demonstrated track records of consistent growth and success in offering customized and highly complementary solutions to support the development of quality of life enhancing and lifesaving therapeutics.

“We are thrilled to add Impact’s complementary service offering and excellent team of qualified, experienced, and dedicated employees to Syner-G,” notes Binesh Prabhakar, co-founder and senior vice president of quality assurance & compliance at Syner-G. “In addition, the transaction will allow Syner-G to have a significant presence in the RTP [Research Triangle Park] area, a fast-growing biotech hub.”